Skip to main content
. 2016 Jan 6;34:509–520. doi: 10.1007/s40273-015-0366-8

Fig. 3.

Fig. 3

Cost-effectiveness acceptability curve by a PAH functional class II and b PAH functional class III at initiation of therapy. QALY quality-adjusted life-year, PAH pulmonary arterial hypertension